19. October 2011 11:38
Par Pharmaceutical has acquired worldwide rights to three products belonging to Teva Pharmaceuticals in connection with the generic pharma company’s buyout of Cephalon.
Under the agreement, Par will own Teva’s fentanyl citrate lozenges, a generic version of Actiq, and the generic version of Amrix (cyclobenzaprine ER capsules). The deal also includes the US market rights to modafinil tablets, the generic version of Provigil.
Annual US sales for Actiq and its equivalent generic products have been reported at $173 million, with $1.1 billion for Provigil, and $125 million for Amrix.
Teva Pharmaceuticals won a race against Valeant to acquire Cephalon, buying the company for $6.8 billion in May 2011.